Biotech & Pharma · Week of Nov 9, 2026
Eli Lilly and Company, Amgen present trial data: the week in biotech
Amgen, Protalix, Immunic, Acurx, Zhengye and Akari also reported; ObesityWeek and ACR Convergence data shared the week with Q3 results.
Conference data led the week. Eli Lilly and Company previewed ObesityWeek 2026 presentations on Zepbound, Foundayo, EloraTZP, eloralintide and retatrutide, and reported one-year TOGETHER-PsA results for Taltz with Zepbound at ACR Convergence 2026. Amgen used the same rheumatology meeting for a late-breaking presentation of Phase 3 dazodalibep data in Sjögren's disease.
The rest of the week was third-quarter and interim reporting by smaller companies. Protalix BioTherapeutics reported net income and reaffirmed revenue guidance. Immunic, Acurx Pharmaceuticals and Akari Therapeutics reported losses and described their cash runway or financing needs alongside upcoming trial milestones. Veterinary vaccine maker Zhengye Biotechnology reported lower six-month revenue and a narrower loss.

Eli Lilly and Company
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
Eli Lilly and Company says it will present data on Zepbound, Foundayo, EloraTZP, eloralintide and retatrutide at ObesityWeek 2026, Nov. 14 to 17. The data include a Phase 2 result in which EloraTZP produced average weight loss of up to 23.3% at 48 weeks, and TRIUMPH-1 results showing retatrutide cut the apnea-hypopnea index by up to 60.6% at 80 weeks.

Eli Lilly and Company
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
Lilly reported 52-week Phase 3b TOGETHER-PsA results, with 43.7% of patients on Taltz plus Zepbound reaching ACR50 versus 15.7% on Taltz alone. The primary endpoint of ACR50 plus at least 10% weight reduction was reached by 39.2% of the combination arm versus 1.7% of the Taltz-alone arm, in adults with psoriatic arthritis and obesity or overweight.

Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
Protalix BioTherapeutics reported third-quarter net income of $4.0 million and nine-month revenues of $75.6 million, including a $25.0 million milestone payment from Chiesi. The company reaffirmed 2026 revenue guidance of approximately $78.0 million to $83.0 million and says Phase 2 RELEASE top-line results for PRX-115 in gout are expected in the second half of 2027.

Immunic, Inc.
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Immunic reported a third-quarter net loss of approximately $42.3 million and cash of $132.0 million, which it expects to fund operations into late 2027. Top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS are expected in December 2026, with a U.S. NDA planned for mid-2027 if results are positive.

Amgen
AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE
Amgen says both dazodalibep regimens met the primary endpoint of reducing ESSDAI versus placebo at Week 48 in the Phase 3 OASIZ-301 study in Sjögren's disease. The 1,500 mg every-four-weeks regimen also improved patient-reported dryness, and full results go to late-breaking session LB22 at ACR Convergence 2026.
Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
Acurx Pharmaceuticals reported a third-quarter net loss of $2.6 million and cash of $9.7 million, and began enrolling its 20-patient PATHFINDER trial of ibezapolstat in multiply-recurrent CDI on September 29, 2026. The company says the trial is fully funded and that it received FDA Conditional Acceptance for CIFBEZY as the drug's proprietary name.
Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026
Zhengye Biotechnology reported six-month net revenue of RMB50.9 million, down 18.3%, as swine vaccine revenue fell to RMB38.2 million. Its net loss narrowed to RMB22.2 million on lower operating expenses, while cash fell to RMB31.9 million from RMB50.3 million at year-end 2025.
Akari Therapeutics Plc
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
Akari Therapeutics reported a third-quarter net loss of approximately $4.8 million and cash of approximately $5.7 million. It has started GLP toxicology studies for ADC candidate AKTX-101 and plans a Phase 1 trial in mid-2027, subject to obtaining additional financing.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Major Health News reporting.